<!doctype html>
<html lang="en">
  <head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Osteoporosis and Bone Metabolism - Clinical Study Note</title>
    <link rel="icon" type="image/png" sizes="48x48" href="/icons/favicon-48.png?v=20260227-favicon1" />
    <link rel="icon" type="image/png" sizes="32x32" href="/icons/favicon-32.png?v=20260227-favicon1" />
    <link rel="icon" type="image/png" sizes="16x16" href="/icons/favicon-16.png?v=20260227-favicon1" />
    <link rel="apple-touch-icon" sizes="180x180" href="/icons/favicon-180.png?v=20260227-favicon1" />
    <style>
      :root {
        --bg: #f8fbff;
        --surface: #ffffff;
        --ink: #132841;
        --muted: #556c84;
        --line: #d7e4f0;
        --brand: #6a4b0f;
        --brand-soft: #fff7ea;
        --teal-soft: #eefaf6;
        --warn-soft: #fff7e8;
        --danger-soft: #fff0f0;
      }

      * {
        box-sizing: border-box;
      }

      body {
        margin: 0;
        font-family: "Segoe UI", Tahoma, Arial, sans-serif;
        color: var(--ink);
        background:
          radial-gradient(circle at 84% 8%, #f6ebcc 0%, transparent 31%),
          radial-gradient(circle at 10% 20%, #e9f4ff 0%, transparent 24%),
          var(--bg);
      }

      .wrap {
        width: min(1240px, 94vw);
        margin: 22px auto 34px;
        display: grid;
        grid-template-columns: 290px 1fr;
        gap: 16px;
      }

      .panel {
        background: var(--surface);
        border: 1px solid var(--line);
        border-radius: 16px;
        box-shadow: 0 10px 24px rgba(13, 34, 62, 0.06);
      }

      .toc {
        position: sticky;
        top: 16px;
        max-height: calc(100dvh - 32px);
        overflow: auto;
        padding: 14px;
      }

      .toc h2 {
        margin: 0 0 10px;
        color: var(--brand);
        font-size: 1rem;
      }

      .toc a {
        display: block;
        text-decoration: none;
        color: #36506c;
        border-radius: 8px;
        padding: 7px 9px;
        font-size: 13px;
      }

      .toc a:hover {
        background: #fff9ef;
        color: #6a4b0f;
      }

      .content {
        padding: 0 0 18px;
      }

      .hero {
        padding: 20px;
        border-bottom: 1px solid var(--line);
        background: linear-gradient(160deg, #ffffff 0%, #fff9ef 56%, #eef7ff 100%);
      }

      .eyebrow {
        display: inline-flex;
        align-items: center;
        min-height: 28px;
        padding: 5px 12px;
        border-radius: 999px;
        background: var(--brand-soft);
        color: #6a4b0f;
        font-size: 12px;
        font-weight: 700;
        margin-bottom: 10px;
      }

      h1 {
        margin: 0;
        color: #563c0c;
        font-size: clamp(1.42rem, 2.4vw, 2.04rem);
      }

      .subtitle {
        margin: 8px 0 0;
        color: var(--muted);
        line-height: 1.55;
      }

      .hero-layout {
        margin-top: 14px;
        display: grid;
        grid-template-columns: 1.35fr 0.95fr;
        gap: 12px;
      }

      .hero-grid {
        display: grid;
        grid-template-columns: repeat(4, minmax(0, 1fr));
        gap: 10px;
      }

      .metric {
        border: 1px solid #efe4cc;
        border-radius: 12px;
        background: #fff;
        padding: 10px;
      }

      .metric .k {
        font-size: 11px;
        color: #7a6c56;
        margin-bottom: 6px;
        text-transform: uppercase;
        letter-spacing: 0.3px;
      }

      .metric .v {
        font-size: 14px;
        color: #563c0c;
        font-weight: 700;
      }

      .hero-visual {
        border: 1px solid #efe4cc;
        border-radius: 14px;
        background: #fff;
        padding: 10px;
        display: grid;
        gap: 8px;
      }

      .hero-visual h3 {
        margin: 0;
        font-size: 0.95rem;
        color: #563c0c;
      }

      .hero-visual p {
        margin: 0;
        font-size: 0.84rem;
        color: #5d758c;
      }

      .hero-visual svg {
        width: 100%;
        height: auto;
        display: block;
      }

      .section {
        padding: 16px 20px;
        border-bottom: 1px solid #edf3fb;
      }

      .section:last-child {
        border-bottom: none;
      }

      .section h2 {
        margin: 0 0 10px;
        color: #563c0c;
        font-size: 1.16rem;
      }

      .section p {
        margin: 0;
        color: #314860;
        line-height: 1.56;
      }

      .stack {
        margin-top: 10px;
        display: grid;
        gap: 10px;
      }

      .grid-2 {
        display: grid;
        grid-template-columns: repeat(2, minmax(0, 1fr));
        gap: 10px;
      }

      .grid-3 {
        display: grid;
        grid-template-columns: repeat(3, minmax(0, 1fr));
        gap: 10px;
      }

      .box {
        border: 1px solid var(--line);
        border-radius: 12px;
        padding: 11px 12px;
        background: #fff;
      }

      .box h3 {
        margin: 0 0 7px;
        font-size: 0.97rem;
        color: #1f4061;
      }

      .box p {
        margin: 0;
      }

      .box ul {
        margin: 0 0 0 17px;
        padding: 0;
      }

      .box li {
        margin: 4px 0;
        color: #304860;
      }

      .table {
        margin-top: 8px;
        width: 100%;
        border-collapse: collapse;
        border-radius: 12px;
        border: 1px solid var(--line);
        overflow: hidden;
      }

      .table th,
      .table td {
        padding: 10px;
        text-align: left;
        font-size: 14px;
        border-bottom: 1px solid #e8eff8;
        vertical-align: top;
      }

      .table th {
        background: #fff9ef;
        color: #563c0c;
      }

      .table tr:last-child td {
        border-bottom: none;
      }

      .chips {
        margin-top: 8px;
        display: flex;
        gap: 8px;
        flex-wrap: wrap;
      }

      .chip {
        display: inline-flex;
        align-items: center;
        min-height: 30px;
        padding: 4px 10px;
        border-radius: 999px;
        border: 1px solid #d8e4f2;
        background: #f8fbff;
        color: #254764;
        font-size: 13px;
        font-weight: 600;
      }

      .callout {
        margin-top: 10px;
        border-left: 4px solid #0f766e;
        border-radius: 10px;
        background: var(--teal-soft);
        color: #175358;
        padding: 10px 12px;
      }

      .callout.warn {
        border-left-color: #b66a00;
        background: var(--warn-soft);
        color: #7c5b1d;
      }

      .callout.alert {
        border-left-color: #b91c1c;
        background: var(--danger-soft);
        color: #6d2222;
      }

      .flow {
        margin-top: 10px;
        display: grid;
        gap: 9px;
      }

      .step {
        border: 1px solid #d5e3f4;
        border-radius: 12px;
        padding: 10px 11px;
        background: #f9fcff;
      }

      .step strong {
        color: #563c0c;
      }

      .arrow {
        width: 30px;
        height: 30px;
        margin: 0 auto;
        border-radius: 999px;
        border: 1px solid #c9d8ec;
        background: #f6fbff;
        color: #456887;
        font-weight: 900;
        display: grid;
        place-items: center;
        line-height: 1;
      }

      .diagram-card {
        margin-top: 10px;
        border: 1px solid #d8e4f2;
        border-radius: 12px;
        background: #fbfdff;
        padding: 11px;
      }

      .diagram-title {
        margin: 0 0 8px;
        font-size: 0.9rem;
        color: #1d3f62;
        font-weight: 700;
      }

      .refs a {
        color: #145aa9;
        text-decoration: none;
        word-break: break-word;
      }

      .refs a:hover {
        text-decoration: underline;
      }

      @media (max-width: 1040px) {
        .wrap {
          grid-template-columns: 1fr;
        }

        .toc {
          position: static;
          max-height: none;
        }

        .hero-layout {
          grid-template-columns: 1fr;
        }

        .hero-grid {
          grid-template-columns: repeat(2, minmax(0, 1fr));
        }
      }

      @media (max-width: 760px) {
        .grid-2,
        .grid-3,
        .hero-grid {
          grid-template-columns: 1fr;
        }
      }
    </style>
  </head>
  <body>
    <div class="wrap">
      <aside class="panel toc">
        <h2>On This Page</h2>
        <a href="#definition">1. Definition</a>
        <a href="#risk-factors">2. Risk Factors</a>
        <a href="#treatment-overview">3. Treatment Overview</a>
        <a href="#calcium-vitamin-d">4. Calcium and Vitamin D</a>
        <a href="#bisphosphonates">5. Bisphosphonates</a>
        <a href="#denosumab">6. Denosumab</a>
        <a href="#teriparatide">7. Teriparatide</a>
        <a href="#romosozumab">8. Romosozumab</a>
        <a href="#serms">9. SERMs</a>
        <a href="#glucocorticoid-induced">10. Glucocorticoid-Induced Osteoporosis</a>
        <a href="#management-recap-drill">Recap Drill</a>
        <a href="#exam-traps">11. Common Exam Traps</a>
        <a href="#quick-revision">12. Quick Revision Summary</a>
      </aside>

      <article class="panel content">
        <header class="hero">
          <span class="eyebrow">Endocrinology</span>
          <h1>Osteoporosis and Bone Metabolism</h1>
          <p class="subtitle">
            Clinical overview and exam mastery guide covering antiresorptive and anabolic therapies,
            dosing regimens, administration rules, and fracture-risk strategy.
          </p>

          <div class="hero-layout">
            <div class="hero-grid">
              <div class="metric">
                <div class="k">Diagnostic Anchor</div>
                <div class="v">T-score -2.5 or lower</div>
              </div>
              <div class="metric">
                <div class="k">First-Line Class</div>
                <div class="v">Bisphosphonates</div>
              </div>
              <div class="metric">
                <div class="k">Denosumab Schedule</div>
                <div class="v">Every 6 months</div>
              </div>
              <div class="metric">
                <div class="k">Teriparatide Limit</div>
                <div class="v">2 years lifetime</div>
              </div>
            </div>

            <div class="hero-visual">
              <h3>Bone Therapy Classes at a Glance</h3>
              <svg viewBox="0 0 500 220" role="img" aria-label="Osteoporosis treatment map">
                <rect x="0" y="0" width="500" height="220" rx="14" fill="#fbfdff" />
                <rect x="20" y="30" width="146" height="72" rx="10" fill="#fff9ef" stroke="#efe4cc" />
                <text x="93" y="54" text-anchor="middle" font-size="13" fill="#563c0c" font-weight="700">Antiresorptive</text>
                <text x="93" y="72" text-anchor="middle" font-size="12" fill="#7a6c56">bisphosphonate</text>
                <text x="93" y="88" text-anchor="middle" font-size="12" fill="#7a6c56">denosumab, SERM</text>

                <rect x="176" y="30" width="146" height="72" rx="10" fill="#eef7ff" stroke="#d8e6f6" />
                <text x="249" y="54" text-anchor="middle" font-size="13" fill="#1f4467" font-weight="700">Anabolic</text>
                <text x="249" y="72" text-anchor="middle" font-size="12" fill="#5f7488">teriparatide</text>
                <text x="249" y="88" text-anchor="middle" font-size="12" fill="#5f7488">romosozumab</text>

                <rect x="332" y="30" width="146" height="72" rx="10" fill="#eefaf7" stroke="#d4ece4" />
                <text x="405" y="54" text-anchor="middle" font-size="13" fill="#1c564f" font-weight="700">Foundation</text>
                <text x="405" y="72" text-anchor="middle" font-size="12" fill="#5b7a74">calcium</text>
                <text x="405" y="88" text-anchor="middle" font-size="12" fill="#5b7a74">vitamin D</text>

                <rect x="20" y="128" width="458" height="68" rx="10" fill="#ffffff" stroke="#d8e4f2" />
                <text x="249" y="154" text-anchor="middle" font-size="13" fill="#2a4963" font-weight="700">
                  Regimen choice is fracture-risk and tolerance based
                </text>
                <text x="249" y="172" text-anchor="middle" font-size="12" fill="#45637e">
                  Oral adherence, renal function, and prior fractures guide escalation
                </text>
              </svg>
              <p>Use antiresorptive or anabolic strategy based on risk severity and contraindications.</p>
            </div>
          </div>
        </header>

        <section class="section" id="definition">
          <h2>1. Definition</h2>
          <p>
            Osteoporosis is decreased bone mass with microarchitectural deterioration,
            causing increased fracture risk. Diagnostic anchors include T-score -2.5 or lower
            or a fragility fracture.
          </p>
        </section>

        <section class="section" id="risk-factors">
          <h2>2. Risk Factors</h2>
          <div class="chips">
            <span class="chip">Postmenopausal state</span>
            <span class="chip">Chronic glucocorticoids</span>
            <span class="chip">Smoking and alcohol</span>
            <span class="chip">Low BMI</span>
            <span class="chip">CKD</span>
            <span class="chip">Hypogonadism</span>
          </div>
        </section>

        <section class="section" id="treatment-overview">
          <h2>3. Treatment Overview</h2>
          <div class="grid-2">
            <div class="box">
              <h3>First-Line for Most</h3>
              <ul>
                <li>Bisphosphonates</li>
              </ul>
            </div>
            <div class="box">
              <h3>Other Options</h3>
              <ul>
                <li>Denosumab</li>
                <li>Teriparatide</li>
                <li>Romosozumab</li>
                <li>SERMs or hormone therapy in selected patients</li>
              </ul>
            </div>
          </div>
        </section>

        <section class="section" id="calcium-vitamin-d">
          <h2>4. Calcium and Vitamin D</h2>
          <table class="table">
            <thead>
              <tr>
                <th>Supplement</th>
                <th>Dose Regimen</th>
                <th>MOA / Role</th>
                <th>Side Effects</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>Calcium</td>
                <td>1000-1200 mg elemental calcium daily, split if over 500 mg per dose</td>
                <td>Provides mineral substrate for bone maintenance</td>
                <td>Constipation, kidney stone risk at excessive dosing</td>
              </tr>
              <tr>
                <td>Vitamin D (cholecalciferol)</td>
                <td>800-1000 IU daily; deficiency repletion 50,000 IU weekly for 6-8 weeks</td>
                <td>Increases calcium absorption and supports mineralization</td>
                <td>Hypercalcemia with excessive intake</td>
              </tr>
            </tbody>
          </table>
        </section>

        <section class="section" id="bisphosphonates">
          <h2>5. Bisphosphonates (First-Line)</h2>
          <p>MOA for class: bind bone surface and inhibit osteoclast-mediated bone resorption.</p>
          <table class="table">
            <thead>
              <tr>
                <th>Agent</th>
                <th>Dose Regimen</th>
                <th>Key Administration / Use</th>
                <th>Side Effects</th>
                <th>Contraindications</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>Alendronate</td>
                <td>70 mg orally weekly or 10 mg daily</td>
                <td>Morning empty stomach, full glass water, remain upright 30 minutes</td>
                <td>Esophagitis, rare jaw osteonecrosis, atypical femur fracture with prolonged use</td>
                <td>Esophageal motility disorders, inability to sit upright, hypocalcemia</td>
              </tr>
              <tr>
                <td>Zoledronic acid</td>
                <td>5 mg IV once yearly</td>
                <td>Useful when oral therapy is not tolerated</td>
                <td>Acute phase flu-like reaction, hypocalcemia</td>
                <td>Severe renal impairment, hypocalcemia</td>
              </tr>
            </tbody>
          </table>
        </section>

        <section class="section" id="denosumab">
          <h2>6. Denosumab</h2>
          <div class="box stack">
            <ul>
              <li>MOA: monoclonal antibody against RANKL, suppressing osteoclast activation</li>
              <li>Dose regimen: 60 mg subcutaneous every 6 months</li>
              <li>Side effects: hypocalcemia, skin infections, rare jaw osteonecrosis</li>
              <li>Contraindication: hypocalcemia</li>
              <li>High-yield caution: abrupt discontinuation can trigger rebound vertebral fractures</li>
            </ul>
          </div>
        </section>

        <section class="section" id="teriparatide">
          <h2>7. Teriparatide</h2>
          <div class="box stack">
            <ul>
              <li>MOA: recombinant PTH analog with intermittent anabolic stimulation of bone formation</li>
              <li>Dose regimen: 20 mcg subcutaneous daily</li>
              <li>Maximum duration: 2 years lifetime</li>
              <li>Side effects: hypercalcemia, dizziness</li>
              <li>Contraindications: bone malignancy risk states, Paget disease</li>
              <li>Use context: severe osteoporosis or multiple fragility fractures</li>
            </ul>
          </div>
        </section>

        <section class="section" id="romosozumab">
          <h2>8. Romosozumab</h2>
          <div class="box stack">
            <ul>
              <li>MOA: sclerostin inhibition increases bone formation and decreases resorption</li>
              <li>Dose regimen: 210 mg subcutaneous monthly</li>
              <li>Maximum duration: 12 months</li>
              <li>Side effect concern: possible increased cardiovascular event risk</li>
              <li>Contraindication: recent myocardial infarction or stroke</li>
            </ul>
          </div>
        </section>

        <section class="section" id="serms">
          <h2>9. SERMs (Raloxifene)</h2>
          <div class="box stack">
            <ul>
              <li>MOA: selective estrogen receptor modulation reduces bone resorption</li>
              <li>Dose regimen: 60 mg orally daily</li>
              <li>Side effects: hot flashes, venous thromboembolism risk</li>
              <li>Contraindication: prior thromboembolic disease</li>
            </ul>
          </div>
        </section>

        <section class="section" id="glucocorticoid-induced">
          <h2>10. Glucocorticoid-Induced Osteoporosis</h2>
          <p>
            Consider treatment when prednisone-equivalent dose is 5 mg/day or more
            for at least 3 months. Preferred initial therapy is often a bisphosphonate.
          </p>
        </section>

        <section class="section" id="management-recap-drill">
          <h2>Management Recap Drill</h2>
          <div class="flow">
            <div class="step"><strong>All patients:</strong> ensure calcium and vitamin D adequacy.</div>
            <div class="arrow" aria-hidden="true">&#8595;</div>
            <div class="step"><strong>First-line:</strong> weekly oral alendronate when tolerated.</div>
            <div class="arrow" aria-hidden="true">&#8595;</div>
            <div class="step"><strong>Oral intolerance:</strong> consider yearly zoledronic acid or denosumab every 6 months.</div>
            <div class="arrow" aria-hidden="true">&#8595;</div>
            <div class="step"><strong>Very high fracture risk:</strong> use anabolic strategy such as teriparatide.</div>
          </div>

          <div class="diagram-card">
            <p class="diagram-title">Visual Algorithm Placeholder</p>
            <p>
              [Insert Osteoporosis Treatment Algorithm Diagram Here During UI Integration]
            </p>
          </div>
        </section>

        <section class="section refs">
          <h2>Guideline References (Management)</h2>
          <div class="grid-2">
            <div class="box">
              <h3>National Osteoporosis Foundation</h3>
              <a href="https://www.nof.org" target="_blank" rel="noopener">
                https://www.nof.org
              </a>
            </div>
            <div class="box">
              <h3>Endocrine Society Guidelines</h3>
              <a href="https://www.endocrine.org" target="_blank" rel="noopener">
                https://www.endocrine.org
              </a>
            </div>
          </div>
          <div class="callout">
            These guidelines cover initiation thresholds, therapy selection, duration, and drug-holiday strategy.
          </div>
        </section>

        <section class="section" id="exam-traps">
          <h2>11. Common Exam Traps</h2>
          <div class="stack">
            <div class="callout alert">Bisphosphonates remain first-line in many patients.</div>
            <div class="callout alert">Oral bisphosphonate administration requires remaining upright for 30 minutes.</div>
            <div class="callout alert">Stopping denosumab abruptly can cause rebound vertebral fracture risk.</div>
            <div class="callout alert">Teriparatide has a 2-year lifetime treatment limit.</div>
            <div class="callout alert">Raloxifene increases venous thromboembolism risk.</div>
          </div>
        </section>

        <section class="section" id="quick-revision">
          <h2>12. Quick Revision Summary</h2>
          <div class="grid-2">
            <div class="box">
              <h3>Must Remember</h3>
              <ul>
                <li>T-score -2.5 or lower indicates osteoporosis</li>
                <li>Weekly alendronate is a common first-line regimen</li>
                <li>Denosumab is given every 6 months</li>
                <li>Teriparatide is bone-anabolic therapy</li>
                <li>Calcium plus vitamin D is foundational for all regimens</li>
              </ul>
            </div>
            <div class="box">
              <h3>Practice Questions Placeholder</h3>
              <ul>
                <li>Topic: Osteoporosis and Bone Metabolism</li>
                <li>
                  Subtopics: bisphosphonates, denosumab, teriparatide, romosozumab,
                  glucocorticoid-induced osteoporosis
                </li>
              </ul>
            </div>
          </div>
        </section>
      </article>
    </div>
  </body>
</html>
